The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2017-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will test whether treatment with N-acetyl-L-cysteine (NAC) is safe and decreases pain in patients with chronic neuropathic pain. The investigators hypothesize that NAC will be a useful adjunct to opioid treatment in chronic neuropathic pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Chronic Pain, Opioid Use, and Epidermal Nerve Fiber Density

NCT04801498

Chronic Pain Opioid Use Nerve Disorders

COMPLETED

Study of Nicotine for Pain Associated With Chemotherapy-Induced Peripheral Neuropathy

NCT04468230

Neuropathy Peripheral Neuropathy Neuropathic Pain +1 more

TERMINATED PHASE2

A Microneurography Study of NaV1.8 Inhibition in Healthy Adults

NCT06420765

Pain

COMPLETED PHASE1

Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer

NCT01196442

COMPLETED NA

Efficacy & Safety Study of Nonracemic Methadone for the Relief of Chronic Peripheral Neuropathic Pain

NCT01429181

Diabetic Peripheral Neuropathic Pain

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open-label study to evaluate the safety and efficacy of N-acetyl-L-cysteine in patients with Chronic neuropathic pain.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuropathic Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

N-acetyl-L-cysteine

n-acetyl-l-cysteine 1200 mg BID x 4 weeks

Group Type EXPERIMENTAL

N-acetyl-l-cysteine

Intervention Type DRUG

1200 mg BID x 4 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

N-acetyl-l-cysteine

1200 mg BID x 4 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NAC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-65 years old
* non-cancer neuropathic pain
* stable dose of opioids for pain
* using breakthrough pain meds
* still with persistent pain per VAS

Exclusion Criteria

* pregnant or nursing
* serious medical or psychiatric illness (including uncontrolled hypertension)
* active stomach ulcer, history or seizures or asthma
* breakthrough pain meds other than opioids
* using illicit drugs

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No